drugset / Trial / NCT00045981

The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)

NCT00045981 ↗

Phase 2 Completed 450 enrolled Synvista Therapeutics, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal dose-ranging study in patients without left ventricular hypertrophy. Eligible patients will be randomized to double-blind treatment once daily for 6 months with oral ALT-711 (35, 70, 140, or 210 mg) or placebo.

Timeline

Start
2001-10
Primary completion
2003-05
Completion
2006-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject alagebrium Small molecule 35 mg Oral
Subject alagebrium Small molecule 70 mg Oral
Subject alagebrium Small molecule 140 mg Oral
Subject alagebrium Small molecule 210 mg Oral

Indications